Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 2/3 to treat alzheimer's disease, as well as in phase 3 to treat parkinson's disease; and is in phase 2 clinical trial to treat lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial to treat later stages of alzheimer's disease and dementia. The company was incorporated in 2008 and is headquartered in Malvern, Pennsylvania. Show more

Location: 101 Lindenwood Drive, Malvern, PA, 19355, United States | Website: https://www.annovisbio.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

45.21M

52 Wk Range

$1.11 - $10.54

Previous Close

$2.37

Open

$2.40

Volume

79,122

Day Range

$2.32 - $2.43

Enterprise Value

28.08M

Cash

17.13M

Avg Qtr Burn

-6.173M

Insider Ownership

14.86%

Institutional Own.

14.58%

Qtr Updated

06/30/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Buntanetap (ANVS401) Details Alzheimer's disease	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Buntanetap (ANVS401) Details Parkinson's disease	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.